These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37794210)

  • 1. Risk of Macrophage Activation Syndrome in Patients with Adult-Onset Still's Disease Treated with IL-1 and IL-6 Inhibitors: A Meta-analysis and Single-Center Experience.
    Adachi S; Takase-Minegishi K; Maeda A; Nagai H; Horita N; Yoshimi R; Kirino Y; Nakajima H
    Rheumatol Ther; 2023 Dec; 10(6):1623-1636. PubMed ID: 37794210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline clinical features predicting macrophage activation syndrome in patients with systemic adult-onset Still's disease receiving interleukin-6 inhibitor treatment.
    Naniwa T; Yamabe T; Ohmura SI; Uehara K; Tamechika SY; Maeda S; Isogai S; Wada J
    Int J Rheum Dis; 2022 Sep; 25(9):1003-1012. PubMed ID: 35719030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrophage activation syndrome in patients with adult-onset Still's disease under tocilizumab treatment: A single-center observational study.
    Yamabe T; Ohmura SI; Uehara K; Naniwa T
    Mod Rheumatol; 2022 Jan; 32(1):169-176. PubMed ID: 33719871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous anakinra to curb cytokine storm in adult-onset Still's disease and in macrophage activation syndrome: A case series.
    Bindoli S; Galozzi P; Doria A; Sfriso P
    Joint Bone Spine; 2023 Mar; 90(2):105524. PubMed ID: 36623798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical characteristics and diagnostic indicators of macrophage activation syndrome in patients with systemic lupus erythematosus and adult-onset Still's disease].
    Yao HH; Yang F; Tang SM; Zhang X; He J; Jia Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Dec; 55(6):966-974. PubMed ID: 38101776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrophage activation syndrome complicating adult onset Still's disease: A single center case series and comparison with literature.
    Lenert A; Yao Q
    Semin Arthritis Rheum; 2016 Jun; 45(6):711-6. PubMed ID: 26672682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of Interleukin-18 as a Diagnostic Biomarker to Differentiate Adult-Onset Still's Disease With/Without Macrophage Activation Syndrome From Other Secondary Hemophagocytic Lymphohistiocytosis in Adults.
    Shiga T; Nozaki Y; Tomita D; Kishimoto K; Hirooka Y; Kinoshita K; Funauchi M; Matsumura I
    Front Immunol; 2021; 12():750114. PubMed ID: 34691064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two cases of adult-onset Still's disease treated with tocilizumab that achieved tocilizumab-free remission.
    Kobayashi D; Ito S; Murasawa A; Narita I; Nakazono K
    Intern Med; 2015; 54(20):2675-9. PubMed ID: 26466710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine profile, ferritin and multi-visceral involvement characterize macrophage activation syndrome during adult-onset Still's disease.
    Ruscitti P; Ursini F; Berardicurti O; Masedu F; Bozzalla Cassione E; Naldi S; Di Cola I; Di Muzio C; De Stefano L; Di Nino E; Navarini L; Vomero M; Bugatti S; Valenti M; Mariani E; Iagnocco A; Montecucco C; Giacomelli R; Cipriani P
    Rheumatology (Oxford); 2022 Dec; 62(1):321-329. PubMed ID: 35438139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of tocilizumab in adult-onset Still's disease: Real-life experience from the international AIDA registry.
    Sota J; Vitale A; Lopalco G; Pereira RMR; Giordano HF; Antonelli IPB; Makowska J; Brzezińska O; Lewandowska-Polak A; Ruscitti P; Cipriani P; Cola ID; Govoni M; Ruffili F; Sfikakis PP; Laskari K; Ragab G; Hussein MA; Gentileschi S; Gaggiano C; La Torre F; Maier A; Emmi G; Marino A; Ciccia F; Sfriso P; Maggio MC; Bartoloni E; Lomater C; Hegazy MT; Tektonidou M; Dagostin MA; Opinc A; Sebastiani GD; Giacomelli R; Giudice ED; Olivieri AN; Tufan A; Kardas RK; Nuzzolese R; Cardinale F; Więsik-Szewczyk E; Veronica P; Tarsia M; Iannone F; Della Casa F; Fabiani C; Frediani B; Balistreri A; Rigante D; Cantarini L
    Semin Arthritis Rheum; 2022 Dec; 57():152089. PubMed ID: 36063578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful Tocilizumab Therapy for Macrophage Activation Syndrome Associated with Adult-Onset Still's Disease: A Case-Based Review.
    Watanabe E; Sugawara H; Yamashita T; Ishii A; Oda A; Terai C
    Case Rep Med; 2016; 2016():5656320. PubMed ID: 27688774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adult-onset still's disease and treatment results with tocilizumab.
    Kır S; Özgen M; Zontul S
    Int J Clin Pract; 2021 Mar; 75(3):e13936. PubMed ID: 33332679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of refractory adult onset Still's disease with tocilizumab-a single centre experience and literature review.
    Reihl Crnogaj M; Čubelić D; Babić A; Mayer M; Anić B
    Rheumatol Int; 2020 Aug; 40(8):1317-1325. PubMed ID: 32506202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrophage activation syndrome associated with adult-onset Still's disease: a multicenter retrospective analysis.
    Wang R; Li T; Ye S; Tan W; Zhao C; Li Y; de Bao C; Fu Q
    Clin Rheumatol; 2020 Aug; 39(8):2379-2386. PubMed ID: 32130578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Case of Macrophage Activation Syndrome During the Treatment of Adult-onset Still's Disease With Tocilizumab.
    Lee JH; Ha YJ; Kang EH; Chang SH; Lee YJ; Sup ; Sup
    J Rheum Dis; 2022 Apr; 29(2):123-128. PubMed ID: 37475901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics of macrophage activation syndrome in adult-onset Still's disease.
    Gao Q; Yuan Y; Wang Y; Jiang J; Ye Z; Liu T; Jiang Z; Zhao L
    Clin Exp Rheumatol; 2021; 39 Suppl 132(5):59-66. PubMed ID: 34251315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophil activation biomarker pentraxin 3 for diagnosis and monitoring of macrophage activation syndrome occurrence in adult-onset Still's disease.
    Zhu D; Chen L; Meng J; Wang M; Ma Y; Chen X; Xiao Y; Yi D; Shi H; Sun Y; Liu H; Cheng X; Su Y; Ye J; Chi H; Zhou Z; Yang C; Teng J; Jia J; Hu Q
    J Autoimmun; 2024 Apr; 144():103182. PubMed ID: 38460457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effectiveness of tocilizumab in treating refractory adult-onset Still's disease with dichotomous phenotypes: IL-18 is a potential predictor of therapeutic response.
    Tang KT; Hsieh CW; Chen HH; Chen YM; Chang SH; Huang PH; Lan JL; Chen DY
    Clin Rheumatol; 2022 Feb; 41(2):557-566. PubMed ID: 34535869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences and similarities in cytokine profiles of macrophage activation syndrome in systemic lupus erythematosus and adult-onset Still's disease.
    Hiyama T; Kurasawa K; Hasegawa A; Miyao T; Tanaka A; Arai S; Arima M; Maezawa R
    Clin Exp Med; 2023 Nov; 23(7):3407-3416. PubMed ID: 36611087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients.
    Ortiz-Sanjuán F; Blanco R; Calvo-Rio V; Narvaez J; Rubio Romero E; Olivé A; Castañeda S; Gallego Flores A; Hernández MV; Mata C; Ros Vilamajo I; Sifuentes Giraldo WA; Caracuel MA; Freire M; Gómez Arango C; Llobet J; Manrique Arija S; Marras C; Moll-Tuduri C; Plasencia-Rodriguez C; Roselló R; Urruticoechea A; Velloso-Feijoo ML; Del Blanco J; González-Vela MC; Rueda-Gotor J; Pina T; Loricera J; González-Gay MA
    Arthritis Rheumatol; 2014 Jun; 66(6):1659-65. PubMed ID: 24515813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.